

Client: Justin Tanger (NHNootropics)

Report No.: TR 054-047C

Date: June 25, 2024

Page: 1

Client: Justin Tanger (NHNootropics) Receipt Date: 6/21/2024
Sample: Bromantane Lot: BN1 Analysis Date: 6/21/2024

Report Date: 6/25/2024 **Matrix:** Powder


Test: Purity Number of samples: 1

Certificate of Analysis

Purity: 99.9%

Data File 20240625_MS2_posneg_Bromantane_lotBN1_ID.d Sample Name Bromantane_lotBN1 Sample Type Sample Position P2-E7 **Instrument Name** Instrument 1 **User Name** Acq Method Bromantane ID.m **Acquired Time** 6/25/2024 1:58:14 PM (UTC-07:00) 20211216_PIS7_165and211_quad_SCAN_POS_Nowar IRM Calibration Not Applicable DA Method taDSDPRWV_neat.m Status Comment **Sample Group** Info. Acquisition Time (Local) Stream Name LC 1 6/25/2024 1:58:14 PM (UTC-07:00) Acquisition SW 6400 Series Triple Quadrupole B.09.00 (B9037.0)

Chromatograms



Peak List

Time	Area	%Area
8.571 min.	28.62	0.1%
11.937 min.	21386.23	99.9%

Reviewed and Approved By:

Herman Lelie

Herman Lelie Ph.D Director of R&D

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control criteria and met method specifications unless otherwise noted.